23 Jul, 2026
According to Straits Research, the global monoclonal antibodies market size was valued at $292,861.03 million in 2025 and is expected to grow from $337,375.9 million in 2026 to $1,046,487.13 million by 2034, registering a CAGR of 15.2% during the forecast period (2026–2034).
Monoclonal antibodies are the laboratory-engineered proteins developed to target specific antigens and stimulate the immune system. These drugs are exact copies of one antibody; therefore, they are named monoclonal antibodies. Based on the source, the monoclonal antibodies are classified into human, humanized, murine, and chimeric. Oncology, inflammatory and autoimmune disorders, infections, and nervous system disorders are treated with monoclonal antibodies. After the approval of the first monoclonal antibody, there is a year-on-year growth was observed in the approvals of monoclonal antibody drugs. Patients can access these medications from hospitals, specialty clinics, and other healthcare facilities.
Rising prevalence of chronic diseases necessitates the demand for monoclonal antibodies
Increasing global incidence of chronic diseases such as cancer, neurological diseases, and autoimmune diseases is one of the drivers propelling the growth of the monoclonal antibodies market. This rise is mainly due to the geriatric population and lack of timely disease diagnosis, fuelling the demand for monoclonal antibody drugs.
This highlighted rise in chronic conditions drives the need for effective medication, which, in turn, supports the market growth.
Surge in the development of advanced monoclonal antibodies: Key market opportunity
Expanding product pipelines and funding for developing novel monoclonal antibodies present numerous opportunities for the monoclonal antibodies market growth during the forecast period.
Furthermore, as healthcare systems shift toward personalized medicine, demand for monoclonal antibodies is expected to increase during the forecast period.
North America is the most significant global monoclonal antibodies market shareholder accounting for 47.09% share in 2024, owing to high prevalence of cancer and autoimmune diseases, availability and accessibility of monoclonal antibodies across the region, and presence of major key players such as Johnson & Johnson, Biogen Inc., and others that offers novel monoclonal antibodies. Additionally, the favourable reimbursement policies, continuous investment in R&D for developing novel targeted monoclonal antibodies further highlight the dominance of North America in the biologics industry.
The Asia-Pacific region is expected to register the fastest CAGR during the forecast period. This growth is attributed to rising awareness of disease management and the use of monoclonal antibodies in chronic care. Furthermore, regional companies such as Takeda Pharmaceuticals are actively engaged in developing new monoclonal antibodies, emerging as a competitive player in the region. Furthermore, the increasing geriatric population that is more prone to chronic diseases such as cancer and gastrointestinal diseases, exacerbates the demand for monoclonal antibodies. Moreover, countries such as China, India, and Japan are witnessing high demand for novel monoclonal antibodies due to a surge in cancer cases. osteoarthritis and other chronic diseases. The shift of foreign manufacturers towards Asia Pacific also makes it the fastest-growing region in the global market.
sales@straitsresearch.com